Additionally, these results have implications for current and emerging clinical trials.Specifically, a recent clinical trial with the CDK4/6i Abemaciclib in EC suggested thatTP53 mutations in the tumor may predict lack of response (15). Here, CDK4 is linked to neoplasm.